Insiders Roll Over 15.7% of Shares in Definitive $2.05B Take-Private Merger at $16.50/Share

summarizeSummary

Executive Chairman Robert A. Ortenzio and other key insiders are rolling over 15.7% of Select Medical's outstanding shares into a new private entity as part of a definitive $2.05 billion take-private merger at $16.50 per share, supported by $1.88 billion in financing.

check_boxKey Events

• Definitive Merger Agreement Signed

  Select Medical Holdings Corp. has entered into a definitive merger agreement to be taken private by a consortium led by its Executive Chairman, Robert A. Ortenzio, for $16.50 per share in cash.

• Significant Insider Rollover

  Executive Chairman Robert A. Ortenzio, Senior EVP Martin F. Jackson, and the Estate of Rocco A. Ortenzio are rolling over approximately 19.5 million shares, representing about 15.7% of outstanding shares, into the new private entity instead of receiving cash.

• Financing Secured

  The take-private transaction is supported by $880 million in equity financing from WCAS XIV, L.P. and $1 billion in debt financing from JPMorgan Chase Bank, N.A., Wells Fargo Bank, N.A., and Wells Fargo Securities LLC, totaling $1.88 billion.

• Shareholder Approval Required

  The merger is subject to approval by a majority of outstanding shares and a majority of shares held by unaffiliated stockholders.

auto_awesomeAnalysis

This Schedule 13D/A filing provides crucial details regarding the previously announced definitive merger agreement for Select Medical Holdings Corp. to be taken private. The filing confirms the merger consideration of $16.50 per share, which represents a slight premium to the current market price. A key aspect is the significant rollover of approximately 19.5 million shares (15.7% of outstanding shares) by Executive Chairman Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson, and the Estate of Rocco A. Ortenzio. This insider commitment signals strong confidence in the company's future under private ownership. The transaction is fully financed with $880 million in equity and $1 billion in debt, ensuring the capital is in place for the acquisition. The merger remains subject to shareholder approval, including a majority vote from unaffiliated stockholders, highlighting the importance of this detailed disclosure for investor decision-making.